Finanzen von Grail Inc (GRAL)GRALGrail Inc

Grail Inc (GRAL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Screening, accounting for 97.7% of total sales, equivalent to $39.83M. Another important revenue stream is Development Services. Understanding this composition is critical for investors evaluating how GRAL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Grail Inc maintains a gross margin of -28.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -332.00%, while the net margin is -246.71%. These profitability ratios, combined with a Return on Equity (ROE) of -16.12%, provide a clear picture of how effectively GRAL converts its operational activities into shareholder value.

In the context of the broader market, GRAL competes directly with industry leaders such as TFX and BLCO. With a market capitalization of $6.25B, it holds a leading position in the sector. When comparing efficiency, GRAL's gross margin of -28.12% stands against TFX's 58.16% and BLCO's 58.11%. Such benchmarking helps identify whether Grail Inc is trading at a premium or discount relative to its financial performance.

Grail's revenue is projected to grow significantly, with estimates of $147 million by 2025, up from $93 million in 2023, indicating strong growth potential in the early cancer detection market.